Abstract
Radium223 is approved for symptomatic castration-resistant prostate cancer patients with osseous involvement. Selecting patients and defining sequence strategies are challenging, with the limited available data, but there is a trend toward greater impact in higher volume disease. Combination and/or consolidation strategies for Radium223 will be of significant interest as data emerge from ongoing trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
